Stock Research: Castle Biosciences

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Castle Biosciences

NMQ:CSTL US14843C1053
57
  • Value
    61
  • Growth
    14
  • Safety
    Safety
    49
  • Combined
    24
  • Sentiment
    90
  • 360° View
    360° View
    57
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Castle Biosciences, Inc. is a diagnostics company improving health through tests that guide patient care. The company operates in the healthcare industry, focusing on diagnostic tests for skin cancers, Barrett’s esophagus, mental health conditions, and uveal melanoma, with products including DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. No specific regions of operation are mentioned. In the last fiscal year, the company had a market cap of $549 million, profits of $272 million, revenue of $332 million, and 761 employees.

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 27-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
61 7 35 26
Growth
14 24 11 55
Safety
Safety
49 79 73 84
Sentiment
90 65 69 47
360° View
360° View
57 25 39 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
100 97 93 97
Opinions Change
50 70 50 26
Pro Holdings
n/a 19 39 3
Market Pulse
78 40 47 72
Sentiment
90 65 69 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
61 7 35 26
Growth
14 24 11 55
Safety Safety
49 79 73 84
Combined
24 13 16 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
44 7 12 3
Price vs. Earnings (P/E)
95 4 78 24
Price vs. Book (P/B)
55 59 80 59
Dividend Yield
1 1 1 1
Value
61 7 35 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
24 4 27 74
Profit Growth
1 92 32 6
Capital Growth
61 6 18 95
Stock Returns
56 53 19 21
Growth
14 24 11 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
72 91 94 90
Refinancing
70 96 92 94
Liquidity
14 4 1 15
Safety Safety
49 79 73 84

Similar Stocks

Discover high‑ranked alternatives to Castle Biosciences and broaden your portfolio horizons.

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Omnicom

NYQ:OMC
Country: USA
Industry: Advertising
Size: X-Large
Full Stock Analysis

Mosaic

NYQ:MOS
Country: USA
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Labcorp

NYQ:LH
Country: USA
Industry: Health Care Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: